Filing Details

Accession Number:
0001615774-17-003262
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-06-20 16:30:21
Reporting Period:
2017-06-19
Filing Date:
2017-06-20
Accepted Time:
2017-06-20 16:30:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1430306 Tonix Pharmaceuticals Holding Corp. TNXP Pharmaceutical Preparations (2834) 261434750
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1563420 Seth Lederman C/O Tonix Pharmaceuticals Holding Corp
509 Madison Ave., Suite 306
New York NY 10022
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.001 Par Value Acquisiton 2017-06-20 20,000 $4.22 20,000 No 4 P Indirect By IRA account
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By IRA account
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, $0.001 Par Value 13,300 Indirect By 401(k) plan
Common Stock, $0.001 Par Value 7,912 Direct
Common Stock, $0.001 Par Value 3,100 Indirect By spouse
Common Stock, $0.001 Par Value 3 Indirect By Leder Laboratories, Inc.
Common Stock, $0.001 Par Value 2,917 Indirect By Starling Pharmaceuticals, Inc.
Common Stock, $0.001 Par Value 18,463 Indirect By Lederman & Co., LLC
Common Stock, $0.001 Par Value 3,246 Indirect By L&L Technologies, LLC
Common Stock, $0.001 Par Value 5,898 Indirect By Targent Pharmaceuticals, LLC
Footnotes
  1. The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $4.220019425. The range of purchase prices on the transaction date was $4.13 to $4.25 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
  2. Reporting person may be deemed to be a control person of this entity.